Growth hormone insensitivity syndromes: Lessons learned and opportunities missed

Ron G. Rosenfeld; Caroline K. Buckway

doi:10.1159/000063472

Growth hormone insensitivity syndromes: Lessons learned and opportunities missed

Ron G. Rosenfeld, Caroline K. Buckway

Pediatrics

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

The concept of growth hormone (GH) insensitivity has evolved since the condition was originally identified in 1966, and we now know that the primary defect involved is in the GH receptor. Cloning of the receptor molecule has led to great progress in our understanding of GH insensitivity (GHI) and its therapy, including the roles of GH and insulin-like growth factor I (IGF-I) in growth and development, and the relationships between height and serum levels of GH, IGF-I and their binding proteins. Despite the success of work on GHI and IGF-I, a number of opportunities have been missed in the past. The differences between the metabolic effects of GH and IGF-I are not fully understood, while measurements of IGF-I and IGF-binding protein 3 are perhaps not the ideal means of diagnosing GHI. Finally, the use of IGF-I to treat GHI has a number of limitations, and work is underway to develop alternative therapies.

Original language	English (US)
Pages (from-to)	36-39
Number of pages	4
Journal	Hormone Research
Volume	55
Issue number	SUPPL. 2
DOIs	https://doi.org/10.1159/000063472
State	Published - 2001

Keywords

Growth hormone
Growth hormone insensitivity
Insulin-like growth factor I
Insulin-like growth factor binding protein 3

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1159/000063472

Cite this

@article{3f0f9a5094af407c9376e2213dd1bc84,

title = "Growth hormone insensitivity syndromes: Lessons learned and opportunities missed",

abstract = "The concept of growth hormone (GH) insensitivity has evolved since the condition was originally identified in 1966, and we now know that the primary defect involved is in the GH receptor. Cloning of the receptor molecule has led to great progress in our understanding of GH insensitivity (GHI) and its therapy, including the roles of GH and insulin-like growth factor I (IGF-I) in growth and development, and the relationships between height and serum levels of GH, IGF-I and their binding proteins. Despite the success of work on GHI and IGF-I, a number of opportunities have been missed in the past. The differences between the metabolic effects of GH and IGF-I are not fully understood, while measurements of IGF-I and IGF-binding protein 3 are perhaps not the ideal means of diagnosing GHI. Finally, the use of IGF-I to treat GHI has a number of limitations, and work is underway to develop alternative therapies.",

keywords = "Growth hormone, Growth hormone insensitivity, Insulin-like growth factor I, Insulin-like growth factor binding protein 3",

author = "Rosenfeld, {Ron G.} and Buckway, {Caroline K.}",

year = "2001",

doi = "10.1159/000063472",

language = "English (US)",

volume = "55",

pages = "36--39",

journal = "Hormone Research",

issn = "0301-0163",

publisher = "S. Karger AG",

number = "SUPPL. 2",

}

TY - JOUR

T1 - Growth hormone insensitivity syndromes

T2 - Lessons learned and opportunities missed

AU - Rosenfeld, Ron G.

AU - Buckway, Caroline K.

PY - 2001

Y1 - 2001

N2 - The concept of growth hormone (GH) insensitivity has evolved since the condition was originally identified in 1966, and we now know that the primary defect involved is in the GH receptor. Cloning of the receptor molecule has led to great progress in our understanding of GH insensitivity (GHI) and its therapy, including the roles of GH and insulin-like growth factor I (IGF-I) in growth and development, and the relationships between height and serum levels of GH, IGF-I and their binding proteins. Despite the success of work on GHI and IGF-I, a number of opportunities have been missed in the past. The differences between the metabolic effects of GH and IGF-I are not fully understood, while measurements of IGF-I and IGF-binding protein 3 are perhaps not the ideal means of diagnosing GHI. Finally, the use of IGF-I to treat GHI has a number of limitations, and work is underway to develop alternative therapies.

AB - The concept of growth hormone (GH) insensitivity has evolved since the condition was originally identified in 1966, and we now know that the primary defect involved is in the GH receptor. Cloning of the receptor molecule has led to great progress in our understanding of GH insensitivity (GHI) and its therapy, including the roles of GH and insulin-like growth factor I (IGF-I) in growth and development, and the relationships between height and serum levels of GH, IGF-I and their binding proteins. Despite the success of work on GHI and IGF-I, a number of opportunities have been missed in the past. The differences between the metabolic effects of GH and IGF-I are not fully understood, while measurements of IGF-I and IGF-binding protein 3 are perhaps not the ideal means of diagnosing GHI. Finally, the use of IGF-I to treat GHI has a number of limitations, and work is underway to develop alternative therapies.

KW - Growth hormone

KW - Growth hormone insensitivity

KW - Insulin-like growth factor I

KW - Insulin-like growth factor binding protein 3

UR - http://www.scopus.com/inward/record.url?scp=0035742063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035742063&partnerID=8YFLogxK

U2 - 10.1159/000063472

DO - 10.1159/000063472

M3 - Article

C2 - 11684874

AN - SCOPUS:0035742063

SN - 0301-0163

VL - 55

SP - 36

EP - 39

JO - Hormone Research

JF - Hormone Research

IS - SUPPL. 2

ER -

Growth hormone insensitivity syndromes: Lessons learned and opportunities missed

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this